1、Optiscan Imaging Limited Appendix 4E Preliminary final report 1.Company details Name of entity:Optiscan Imaging Limited ABN:81 077 771 987 Reporting period:For the year ended 30 June 2018 Previous period:For the year ended 30 June 2017 2.Results for announcement to the market$Revenues from ordinary
2、activities up 62.9%to 2,197,548 Loss from ordinary activities after tax attributable to the owners of Optiscan Imaging Limited down 30.8%to (2,035,328)Loss for the year attributable to the owners of Optiscan Imaging Limited down 30.8%to (2,035,328)Dividends There were no dividends paid,recommended o
3、r declared during the current financial period.Comments The loss for the consolidated entity after providing for income tax amounted to$2,035,328(30 June 2017:$2,942,925).Financial performance During the financial year,the consolidated entity generated ordinary revenue of$1,928,283 from the sale of
4、systems and components to Carl Zeiss Meditech(CZM),compared to revenue for the year ended 30 June 2017 of$1,333,263.The total revenue from ordinary activities including the sale of ViewnVivo systems increased by 63%to$2,197,548.The consolidated entity also recorded research and development incentive
5、 income for the financial year of$781,758,a decrease of$198,499 from the previous financial year(2017:$980,257).The increase in expenses during the financial year was as a result of an increase in administration expenditure,including higher staff and marketing costs.Research and development costs de
6、creased by$233,053 to$1,974,733(2017:$2,207,786).Financial Position The net assets increased by$1,536,066 to$3,201,425 at 30 June 2018(30 June 2017:$1,665,359).The working capital position of the consolidated entity as at 30 June 2018 was an excess of current assets over current liabilities of$2,806